A Phase 2 Study of M6620 in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Berzosertib (Primary) ; Carboplatin (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 11 Apr 2019 Planned End Date changed from 6 Dec 2020 to 31 Dec 2021.
- 11 Apr 2019 Planned primary completion date changed from 6 Dec 2020 to 31 Dec 2021.
- 19 Mar 2019 Status changed from not yet recruiting to recruiting.